Efficacy and Safety of Dexmedetomidine to Bupivacaine in Supraclavicular Brachial Plexus Block

NACompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

October 9, 2023

Primary Completion Date

March 11, 2024

Study Completion Date

March 11, 2024

Conditions
DexmedetomidineBupivacaineSupraclavicular Brachial Plexus Block
Interventions
DRUG

bupivacaine and dexmedetomidine.

patient will receive Ultrasound -guided Supraclavicular brachial plexus block with 20 ml bupivacaine 0.5% + 1 μg/kg dexmedetomidine.

DRUG

bupivacaine only

patient will receive Ultrasound -guided Supraclavicular brachial plexus block with 20 ml bupivacaine 0.5% without additives

DRUG

bupivacaine

patient will receive Ultrasound -guided Supraclavicular brachial plexus block with 30 ml bupivacaine 0.5% without additives as a control group.

Trial Locations (1)

33516

Kafrelsheikh University, Kafr ash Shaykh

All Listed Sponsors
lead

Kafrelsheikh University

OTHER